ArticleRNA (New York, N.Y.)2019
An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.
Article in RNA (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates.Nucleic acids research · 2024Article
- Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system.Journal of translational medicine · 2024Review
- Ligand conjugate SAR and enhanced delivery in NHP.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Current and Prospective Targets of Pharmacologic Treatment of Hereditary Angioedema Types 1 and 2.Clinical reviews in allergy & immunology · 2021Review
- Pathophysiology of Hereditary Angioedema (HAE) Beyond the SERPING1 Gene.Clinical reviews in allergy & immunology · 2021Review
- Clinical manifestations of hereditary angioedema and a systematic review of treatment options.Laryngoscope investigative otolaryngology · 2021Review
- High Estrogen States in Hereditary Angioedema: a Spectrum.Clinical reviews in allergy & immunology · 2021Review
- Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine.Clinical reviews in allergy & immunology · 2021Review
- Article
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
- Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation.Nature communications · 2020Article
- The FXII c.-4T>C Polymorphism as a Disease Modifier in Patients With Hereditary Angioedema Due to the FXII p.Thr328Lys Variant.Frontiers in genetics · 2020Article
- RNA delivery biomaterials for the treatment of genetic and rare diseases.Biomaterials · 2019Review
- Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.Drug design, development and therapy · 2019Review
- Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research.Drugs in context · 2019Review
- Emerging Therapies in Hereditary Angioedema.Immunology and allergy clinics of North America · 2017Review
- Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy.Thrombosis journal · 2017Review
- Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI.Expert review of hematologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema (HAE) is a genetic disorder mostly caused by mutations in the C1 esterase inhibitor gene (C1INH) that results in poor control of contact pathway activation and excess bradykinin generation. Bradykinin increases vascular permeability and is ultimately responsible for the episodes of swelling characteristic of HAE. We hypothesized that the use of RNA interference (RNAi) to reduce plasma Factor XII (FXII), which initiates the contact pathway signaling cascade, would reduce contact pathway activation and prevent excessive bradykinin generation. A subcutaneously administered GalNAc-conjugated small-interfering RNA (siRNA) targeting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.